Small study aims to unravel Statins' muscle side effects

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Male and Female, Age ≥ 65 y to 80 y * BMI \>20 but less than or equal to 35 * Currently taking a cholesterol lowering statin * Stable body-weight (± 5%) for the past 3 months * Subject is judged to be in satisfactory health based on medical history, physical examination, and laboratory screening evaluations. * Ability to walk, sit down and stand up independently * Ability to lie in supine or elevated position for up to 8 hours * Willingness and ability to comply with the protocol Exclusion criteria: * Metabolic diseases including diabetes, hepatic or renal disorder * Subject has malignant disease or autoimmune disease * Subject has impaired liver function * Subject has had a significant cardiovascular event (e.g. myocardial infarction, stroke) ≤ 6 months prior to screening visit; or stated history of congestive heart failure * Subject has current significantly impaired liver function in the opinion of the study PI (mild asymptomatic fatty liver is acceptable), or hepatic enzyme tests are ≥2.5 times normal limit * Subject has a chronic, contagious, infectious disease, such as active tuberculosis, hepatitis B or C, or HIV * Subject has chronic disease such as COPD * Subject is expected to have surgery within one-month of screening * Subject is currently participating or has participated in a study with an investigational compound or device within 30 days of signing the informed consent. * Presence of acute illness or metabolically unstable chronic illness (unrelated to the primary disease) * Unwilling to stop taking nutritional protein supplements within 5 days of first study day * Any other condition according to the PI or nurse that would interfere with the study or safety of the subject or influence the results * Presence of fever within the last 3 days * Untreated metabolic diseases including hepatic or renal disorder unrelated to the primary disease * Active dependence of alcohol or drugs * Medication: Use of substances known to influence amino acid metabolism: antibiotics within 3 weeks prior to the study visit, current use of corticosteroids, growth hormone, testosterone, estrogen, immunosuppressant, blood thinners, or insulin. * Subject cannot refrain from taking dietary supplements/substances that could modulate metabolism or weight in the opinion of the principal investigator or physician, starting four weeks prior to enrollment and over the entire course of the study such as b-hydroxy-b-methyl butyrate (HMB) or products containing HMB * Adherence to a weight loss diet. * Currently taking any drugs that impact liver function * Subject having elevated blood CK/CPK levels (3-10X above normal range)